Joana F. S. Pereira

Joana F. S. Pereira

Auto-generated profile, based on publicly available information

Joana F. S. Pereira

Department of Human Genetics, National Institute of Health ‘Dr. Ricardo Jorge’, 1649-016 Lisbon, Portugal

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 February 2014 in RNA
Verified
Journal Article
Open access
PDF file
VGVânia Gonçalves
Vânia Gonçalves
AHAndreia Almeida Henriques
Andreia Almeida Henriques
JPJoana Pereira
Joana Pereira
ACAna Neves Costa
Ana Neves Costa
MMMary Pat Moyer
Mary Pat Moyer
Peter JordanPeter Jordan
Peter Jordan
The premessenger RNA of the majority of human genes can generate various transcripts through alternative splicing, and different tissues or disease states show specific patterns of splicing variants. These patterns depend on the relative concentrations of the splicing factors present in the cell nucleus, either as a consequence of their expression levels or of post-translational modifications, such as protein phosphorylation, which are determined by signal transduction pathways. Here, we analyzed the contribution of protein kinases to the regulation of alternative splicing variant Rac1b that is overexpressed in certain tumor types. In colorectal cells, we found that depletion of AKT2, AKT3, GSK3β, and SRPK1 significantly decreased endogenous Rac1b levels. Although knockdown of AKT2 and AKT3 affected only Rac1b protein levels suggesting a post-splicing effect, the depletion of GSK3β or SRPK1 decreased Rac1b alternative splicing, an effect mediated through changes in splicing factor SRSF1. In particular, the knockdown of SRPK1 or inhibition of its catalytic activity reduced phosphorylation and subsequent translocation of SRSF1 to the nucleus, limiting its availability to promote the inclusion of alternative exon 3b into the Rac1 pre-mRNA. Altogether, the data identify SRSF1 as a prime regulator of Rac1b expression in colorectal cells and provide further mechanistic insight into how the regulation of alternative splicing events by protein kinases can contribute to sustain tumor cell survival.

9 November 2014 in Endocrine
Verified
Journal Article
Closed access
PDF file
JPJoana S. Pereira
Joana S. Pereira
JSJoana Gomes da Silva
Joana Gomes da Silva
RTRute Alexandra Tomaz
Rute Alexandra Tomaz
APAntónio Evaristo Pinto
António Evaristo Pinto
Maria João BugalhoMaria João Bugalho
Maria João Bugalho
BCBranca Maria Cavaco
Branca Maria Cavaco

29 December 2017 in Genes
Verified
Journal Article
Open access
PDF file
VGVânia Gonçalves
Vânia Gonçalves
JPJoana F. S. Pereira
Joana F. S. Pereira
Peter JordanPeter Jordan
Peter Jordan
Aberrant profiles of pre-mRNA splicing are frequently observed in cancer. At the molecular level, an altered profile results from a complex interplay between chromatin modifications, the transcriptional elongation rate of RNA polymerase, and effective binding of the spliceosome to the generated transcripts. Key players in this interplay are regulatory splicing factors (SFs) that bind to gene-specific splice-regulatory sequence elements. Although mutations in genes of some SFs were described, a major driver of aberrant splicing profiles is oncogenic signal transduction pathways. Signaling can affect either the transcriptional expression levels of SFs or the post-translational modification of SF proteins, and both modulate the ratio of nuclear versus cytoplasmic SFs in a given cell. Here, we will review currently known mechanisms by which cancer cell signaling, including the mitogen-activated protein kinases (MAPK), phosphatidylinositol 3 (PI3)-kinase pathway (PI3K) and wingless (Wnt) pathways but also signals from the tumor microenvironment, modulate the activity or subcellular localization of the Ser/Arg rich (SR) proteins and heterogeneous nuclear ribonucleoproteins (hnRNPs) families of SFs.

19 May 2015 in Science Signaling
Verified
Journal Article
Closed access
PDF file
CLCláudia A. Loureiro
Cláudia A. Loureiro
AMAna Matos
Ana Matos
ÂDÂngela Dias-Alves
Ângela Dias-Alves
JPJoana F. Pereira
Joana F. Pereira
IUInna Uliyakina
Inna Uliyakina
PMPaulo Matos
Paulo Matos
The peripheral protein quality control (PPQC) checkpoint removes improperly folded proteins from the plasma membrane through a mechanism involving the E3 ubiquitin ligase CHIP (carboxyl terminus of Hsc70 interacting protein). PPQC limits the efficacy of some cystic fibrosis (CF) drugs, such as VX-809, that improve trafficking to the plasma membrane of misfolded mutants of the CF transmembrane conductance regulator (CFTR), including F508del-CFTR, which retains partial functionality. We investigated the PPQC checkpoint in lung epithelial cells with F508del-CFTR that were exposed to VX-809. The conformation of the scaffold protein NHERF1 (Na+/H+ exchange regulatory factor 1) determined whether the PPQC recognized “rescued” F508del-CFTR (the portion that reached the cell surface in VX-809–treated cells). Activation of the cytoskeletal regulator Rac1 promoted an interaction between the actin-binding adaptor protein ezrin and NHERF1, triggering exposure of the second PDZ domain of NHERF1, which interacted with rescued F508del-CFTR. Because binding of F508del-CFTR to the second PDZ of NHERF1 precluded the recruitment of CHIP, the coexposure of airway cells to Rac1 activator nearly tripled the efficacy of VX-809. Interference with the NHERF1-ezrin interaction prevented the increase of efficacy of VX-809 by Rac1 activation, but the actin-binding domain of ezrin was not required for the increase in efficacy. Thus, rather than mainly directing anchoring of F508del-CFTR to the actin cytoskeleton, induction of ezrin activation by Rac1 signaling triggered a conformational change in NHERF1, which was then able to bind and stabilize misfolded CFTR at the plasma membrane. These insights into the cell surface stabilization of CFTR provide new targets to improve treatment of CF.

21 September 2022 in Nanomaterials
Verified
Journal Article
Open access
PDF file
DRDora Rolo
Dora Rolo
Ricardo AssunçãoRicardo Assunção
Ricardo Assunção
CVCélia Ventura
Célia Ventura
PAPaula Alvito
Paula Alvito
Luís Miguel GoncalvesLuís Miguel Goncalves
Luís Miguel Goncalves
Henriqueta LouroHenriqueta Louro
Henriqueta Louro
Titanium dioxide nanoparticles (TiO2-NPs) are widely used, and humans are exposed through food (E171), cosmetics (e.g., toothpaste), and pharmaceuticals. The oral and gastrointestinal (GIT) tract are the first contact sites, but it may be systemically distributed. However, a robust adverse outcome pathway (AOP) has not been developed upon GIT exposure to TiO2-NPs. The aim of this review was to provide an integrative analysis of the published data on cellular and molecular mechanisms triggered after the ingestion of TiO2-NPs, proposing plausible AOPs that may drive policy decisions. A systematic review according to Prisma Methodology was performed in three databases of peer-reviewed literature: Pubmed, Scopus, and Web of Science. A total of 787 records were identified, screened in title/abstract, being 185 used for data extraction. The main endpoints identified were oxidative stress, cytotoxicity/apoptosis/cell death, inflammation, cellular and systemic uptake, genotoxicity, and carcinogenicity. From the results, AOPs were proposed where colorectal cancer, liver injury, reproductive toxicity, cardiac and kidney damage, as well as hematological effects stand out as possible adverse outcomes. The recent transgenerational studies also point to concerns with regard to population effects. Overall, the findings further support a limitation of the use of TiO2-NPs in food, announced by the European Food Safety Authority (EFSA).

4 May 2016 in Cellular and Molecular Life Sciences
Verified
Journal Article
Closed access
PDF file
JPJoana F. S. Pereira
Joana F. S. Pereira
NANikhil Awatade
Nikhil Awatade
CLCláudia A. Loureiro
Cláudia A. Loureiro
PMPaulo Matos
Paulo Matos
MAMargarida Amaral
Margarida Amaral
Peter JordanPeter Jordan
Peter Jordan